insitro

Company profile

About insitro

insitro is an AI therapeutics company that is redefining drug discovery and development by combining massive-scale cellular experiments with population-scale genetics. The company has built the Virtual Human™, a genetically anchored, causal AI engine built on the world's largest integrated multimodal corpus of human clinical and cellular data. This platform reveals how disease begins, progresses, and can be resolved by precisely identifying causal disease targets prior to candidate optimization. insitro's TherML™ is a modality-agnostic, AI-driven therapeutics design engine spanning small molecules, oligonucleotides, and complex biologics. By matching the best-fit modality to each target and indication, TherML shifts drug discovery from stochastic screening to predictive, adaptive engineering. The company has built a unique culture where life scientists, data scientists, engineers, and drug hunters work together to identify the most important questions, design and scale experiments, build models, and analyze results. insitro's approach integrates human data to understand which biological changes matter for disease with cellular data to determine what causes those changes, using AI to identify mechanisms consistent at both scales. The company is advancing multiple therapeutic programs including MASH, ALS, and metabolic diseases through strategic collaborations with major pharmaceutical companies.

Company description · insitro official website

Mission. At insitro, we are building a different kind of drug company to bring better drugs faster to the patients who can benefit most. Through the power of machine learning (ML) and data at scale, we decode the complexities of biology to unlock transformative new medicines.